[Pembrolizumab in triple-negative breast cancer]
Lazo E, Mejía J, García Martí S, Alfie V, Perelli L, Cantos J, Augustovski F, Pichon Riviere A, Ciapponi A, Alcaraz A, Bardach A
Record ID 32018012833
Spanish
Original Title:
Pembrolizumab en cáncer de mama triple negativo en etapa temprana o localmente avanzado (neoadyuvancia/ adyuvancia)
Authors' recommendations:
"Conclusions
High-quality evidence suggests that neoadjuvant pembrolizumab in combination with chemotherapy followed by adjuvant pembrolizumab provides a significant net benefit when compared with neoadjuvant chemotherapy for the treatment of early stage or locally advanced triple-negative breast cancer because it increases progression free survival and complete disease response. Despite a higher incidence of adverse events was registered, a significant increase of severe adverse effects was not observed.
Most clinical practice guidelines developed for early stage or locally advanced triple-negative breast cancer, including the one from Argentina, recommend neoadjuvant therapy with pembrolizumab, paclitaxel and carboplatin followed by doxorubicin and cyclophosphamide as scheme of choice. In addition, they recommend the use of pembrolizumab as adjuvant therapy.
Health funders from high-income countries cover pembrolizumab as neoadjuvant and adjuvant therapy in patients with early stage triple-negative breast cancer at high risk of relapse. However, Latin American health funders do not mention it or define a specific indication for this drug in this group of patients.
As regards economic evaluations, pembrolizumab has shown it is a cost-effective treatment option for patients with early stage or locally advanced triple-negative breast cancer in the United States from the funder’s point of view. However, although no economic evaluations carried out in Argentina have been found for this technology, there are elements to consider it would not be cost-effective due to its high cost versus its comparator."
Details
Project Status:
Completed
URL for project:
https://ets.iecs.org.ar/publication/2102
Year Published:
2023
URL for published report:
https://ets.iecs.org.ar/publication/2102
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Argentina
MeSH Terms
- Breast Neoplasms
- Triple Negative Breast Neoplasms
- Antineoplastic Combined Chemotherapy Protocols
- Antibodies, Monoclonal, Humanized
- Immune Checkpoint Inhibitors
- Neoadjuvant Therapy
Contact
Organisation Name:
Institute for Clinical Effectiveness and Health Policy
Contact Address:
Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name:
info@iecs.org.ar
Contact Email:
info@iecs.org.ar
Copyright:
<p>Institute for Clinical Effectiveness and Health Policy (IECS)</p>
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.